27 research outputs found
Phase transition in PCA with missing data: Reduced signal-to-noise ratio, not sample size!
How does missing data affect our ability to learn signal structures? It has
been shown that learning signal structure in terms of principal components is
dependent on the ratio of sample size and dimensionality and that a critical
number of observations is needed before learning starts (Biehl and Mietzner,
1993). Here we generalize this analysis to include missing data. Probabilistic
principal component analysis is regularly used for estimating signal structures
in datasets with missing data. Our analytic result suggests that the effect of
missing data is to effectively reduce signal-to-noise ratio rather than - as
generally believed - to reduce sample size. The theory predicts a phase
transition in the learning curves and this is indeed found both in simulation
data and in real datasets.Comment: Accepted to ICML 2019. This version is the submitted pape
not-MIWAE: Deep Generative Modelling with Missing not at Random Data
When a missing process depends on the missing values themselves, it needs to
be explicitly modelled and taken into account while doing likelihood-based
inference. We present an approach for building and fitting deep latent variable
models (DLVMs) in cases where the missing process is dependent on the missing
data. Specifically, a deep neural network enables us to flexibly model the
conditional distribution of the missingness pattern given the data. This allows
for incorporating prior information about the type of missingness (e.g.
self-censoring) into the model. Our inference technique, based on
importance-weighted variational inference, involves maximising a lower bound of
the joint likelihood. Stochastic gradients of the bound are obtained by using
the reparameterisation trick both in latent space and data space. We show on
various kinds of data sets and missingness patterns that explicitly modelling
the missing process can be invaluable.Comment: Camera-ready version for ICLR 202
How to deal with missing data in supervised deep learning?
International audienceThe issue of missing data in supervised learning has been largely overlooked, especially in the deep learning community. We investigate strategies to adapt neural architectures for handling missing values. Here, we focus on regression and classification problems where the features are assumed to be missing at random. Of particular interest are schemes that allow reusing as-is a neural discriminative architecture. To address supervised deep learning with missing values, we propose to marginalize over missing values in a joint model of covariates and outcomes. Thereby, we leverage both the flexibility of deep generative models to describe the distribution of the covariates and the power of purely discriminative models to make predictions. More precisely, a deep latent variable model can be learned jointly with the discriminative model, using importance-weighted variational inference, essentially using importance sampling to mimick averaging over multiple imputations. In low-capacity regimes, or when the discriminative model has a strong inductive bias, we find that our hybrid generative/discriminative approach generally outperforms single imputations methods
A Federated Database for Obesity Research:An IMI-SOPHIA Study
Obesity is considered by many as a lifestyle choice rather than a chronic progressive disease. The Innovative Medicines Initiative (IMI) SOPHIA (Stratification of Obesity Phenotypes to Optimize Future Obesity Therapy) project is part of a momentum shift aiming to provide better tools for the stratification of people with obesity according to disease risk and treatment response. One of the challenges to achieving these goals is that many clinical cohorts are siloed, limiting the potential of combined data for biomarker discovery. In SOPHIA, we have addressed this challenge by setting up a federated database building on open-source DataSHIELD technology. The database currently federates 16 cohorts that are accessible via a central gateway. The database is multi-modal, including research studies, clinical trials, and routine health data, and is accessed using the R statistical programming environment where statistical and machine learning analyses can be performed at a distance without any disclosure of patient-level data. We demonstrate the use of the database by providing a proof-of-concept analysis, performing a federated linear model of BMI and systolic blood pressure, pooling all data from 16 studies virtually without any analyst seeing individual patient-level data. This analysis provided similar point estimates compared to a meta-analysis of the 16 individual studies. Our approach provides a benchmark for reproducible, safe federated analyses across multiple study types provided by multiple stakeholders
A Federated Database for Obesity Research:An IMI-SOPHIA Study
Obesity is considered by many as a lifestyle choice rather than a chronic progressive disease. The Innovative Medicines Initiative (IMI) SOPHIA (Stratification of Obesity Phenotypes to Optimize Future Obesity Therapy) project is part of a momentum shift aiming to provide better tools for the stratification of people with obesity according to disease risk and treatment response. One of the challenges to achieving these goals is that many clinical cohorts are siloed, limiting the potential of combined data for biomarker discovery. In SOPHIA, we have addressed this challenge by setting up a federated database building on open-source DataSHIELD technology. The database currently federates 16 cohorts that are accessible via a central gateway. The database is multi-modal, including research studies, clinical trials, and routine health data, and is accessed using the R statistical programming environment where statistical and machine learning analyses can be performed at a distance without any disclosure of patient-level data. We demonstrate the use of the database by providing a proof-of-concept analysis, performing a federated linear model of BMI and systolic blood pressure, pooling all data from 16 studies virtually without any analyst seeing individual patient-level data. This analysis provided similar point estimates compared to a meta-analysis of the 16 individual studies. Our approach provides a benchmark for reproducible, safe federated analyses across multiple study types provided by multiple stakeholders.</p
A Federated Database for Obesity Research:An IMI-SOPHIA Study
Obesity is considered by many as a lifestyle choice rather than a chronic progressive disease. The Innovative Medicines Initiative (IMI) SOPHIA (Stratification of Obesity Phenotypes to Optimize Future Obesity Therapy) project is part of a momentum shift aiming to provide better tools for the stratification of people with obesity according to disease risk and treatment response. One of the challenges to achieving these goals is that many clinical cohorts are siloed, limiting the potential of combined data for biomarker discovery. In SOPHIA, we have addressed this challenge by setting up a federated database building on open-source DataSHIELD technology. The database currently federates 16 cohorts that are accessible via a central gateway. The database is multi-modal, including research studies, clinical trials, and routine health data, and is accessed using the R statistical programming environment where statistical and machine learning analyses can be performed at a distance without any disclosure of patient-level data. We demonstrate the use of the database by providing a proof-of-concept analysis, performing a federated linear model of BMI and systolic blood pressure, pooling all data from 16 studies virtually without any analyst seeing individual patient-level data. This analysis provided similar point estimates compared to a meta-analysis of the 16 individual studies. Our approach provides a benchmark for reproducible, safe federated analyses across multiple study types provided by multiple stakeholders.</p
A Federated Database for Obesity Research: An IMI-SOPHIA Study
Obesity is considered by many as a lifestyle choice rather than a chronic progressive disease. The Innovative Medicines Initiative (IMI) SOPHIA (Stratification of Obesity Phenotypes to Optimize Future Obesity Therapy) project is part of a momentum shift aiming to provide better tools for the stratification of people with obesity according to disease risk and treatment response. One of the challenges to achieving these goals is that many clinical cohorts are siloed, limiting the potential of combined data for biomarker discovery. In SOPHIA, we have addressed this challenge by setting up a federated database building on open-source DataSHIELD technology. The database currently federates 16 cohorts that are accessible via a central gateway. The database is multi-modal, including research studies, clinical trials, and routine health data, and is accessed using the R statistical programming environment where statistical and machine learning analyses can be performed at a distance without any disclosure of patient-level data. We demonstrate the use of the database by providing a proof-of-concept analysis, performing a federated linear model of BMI and systolic blood pressure, pooling all data from 16 studies virtually without any analyst seeing individual patient-level data. This analysis provided similar point estimates compared to a meta-analysis of the 16 individual studies. Our approach provides a benchmark for reproducible, safe federated analyses across multiple study types provided by multiple stakeholders